

ENSAYOS CLÍNICOS MELANOMA Y TUMORES CUTÁNEOS

- MELANOMA

EC MK3475-716

"Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)"

<https://clinicaltrials.gov/ct2/show/NCT03553836?term=MK3475-716&rank=1>

CA045-001

"A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma"

<https://clinicaltrials.gov/ct2/show/NCT03635983?term=CA045-001&rank=1>

MK7902-003

"A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)"

<https://clinicaltrials.gov/ct2/show/NCT03820986?term=MK7902-003&rank=1>

MO39136

"A PHASE II TWO COHORT STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB PLUS ATEZOLIZUMAB IN BRAFV600 WILD-TYPE MELANOMA WITH CENTRAL NERVOUS SYSTEM METASTASES AND COBIMETINIB PLUS ATEZOLIZUMAB AND VEMURAFENIB IN BRAFV600 MUTATION-POSITIVE MELANOMA WITH CENTRAL NERVOUS SYSTEM METASTASES"

<https://clinicaltrials.gov/ct2/show/NCT03625141?term=MO39136&rank=1>

CPDR001J2201

"A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma"

<https://clinicaltrials.gov/ct2/show/NCT03484923?term=CPDR001J2201&rank=1>

MK7902-004

"A Multicenter, Open-label, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) in Participants with Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent (LEAP-004)"

<https://clinicaltrials.gov/ct2/show/NCT03776136?term=MK7902-004&rank=1>

2125-MEL-301

"A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma"

<https://clinicaltrials.gov/ct2/show/NCT03445533?term=2125-MEL-301&rank=1>

INCMGA 0012-201

"A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma"

<https://clinicaltrials.gov/ct2/show/NCT03599713?term=INCMGA+0012-201&rank=1>

- CABEZA Y CUELLO

WO40242

"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH-RISK LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK"

<https://clinicaltrials.gov/ct2/show/NCT03452137?term=WO40242&rank=1>

- PULMON

BO29554 (B-FAST)

"A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL) "

<https://clinicaltrials.gov/ct2/show/NCT03178552?term=BO29554&rank=1>

MS200095-0022

"A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION)"

<https://clinicaltrials.gov/ct2/show/NCT02864992?term=MS200095-0022&rank=1>

LUNAR (EF-24)

"Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure"

<https://clinicaltrials.gov/ct2/show/NCT02973789?term=LUNAR+%28EF-24%29&rank=1>

CINC280A2201

"A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced nonsmall cell lung cancer (NSCLC)"

<https://clinicaltrials.gov/ct2/show/NCT02414139?term=CINC280A2201&rank=1>

MK3475-671

"A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)"

<https://clinicaltrials.gov/ct2/show/NCT03425643?term=MK3475-671&rank=1>

CINC280D2201

"A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adult patients with EGFR wild-type, ALK rearrangement negative locally advanced/metastatic non-small cell lung cancer."

<https://clinicaltrials.gov/ct2/show/NCT03647488?term=CINC280D2201&rank=1>

CACZ885T2301

"A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-III A and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)"

<https://clinicaltrials.gov/ct2/show/NCT03447769?term=CACZ885T2301&rank=1>

- SARCOMAS

GEIS 40

"Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line setting for patients with metastatic and/or unresectable KIT/PDGFR Wild Type GIST"

<https://clinicaltrials.gov/ct2/show/NCT02638766?term=REGISTRI&rank=1>

GEIS 42

"Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study"

<https://clinicaltrials.gov/ct2/show/NCT02413736?term=SSGXII&rank=1>

GEIS 51

"Ensayo fase II multicéntrico de palbociclib en segunda línea de sarcomas avanzados con sobreexpresión CDK4"

<https://clinicaltrials.gov/ct2/show/NCT03242382?term=GEIS+51&rank=1>